ACRVAcrivon Therapeutics, Inc.同业对比
Acrivon Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACRV本股 | $78M#6 | — | 0.9x#3 | — | — | 3.3%#2 | — | -89.9%#5 | — | — | 19.3%#1 | — |
| LFVN | $79M#2 | 15.8x#1 | 2.4x#6 | 0.4x#1 | -20.1%#4 | -48.3%#9 | 3.3%#1 | 15.1%#2 | 28.2%#1 | 6#1 | -39.1%#3 | 3.0%#1 |
| CTOR | $80M#1 | — | 2.0x#5 | — | — | -17.1%#4 | — | -61.3%#4 | — | — | — | — |
| VRCA | $79M#3 | — | 18.2x#11 | 2.2x#2 | 370.2%#2 | 76.6%#1 | -34.2%#2 | -415.6%#11 | -36.1%#2 | — | -9.7%#2 | — |
| LEXX | $78M#4 | — | 16.5x#10 | 110.6x#4 | 52.0%#3 | -105.4%#10 | -1683.0%#4 | -251.2%#10 | — | — | -83.6%#4 | — |
| RNXT | $78M#5 | — | 8.7x#9 | 69.5x#3 | 2511.6%#1 | -26.7%#5 | -1114.0%#3 | -124.4%#8 | — | — | — | — |
| GANX | $75M#7 | — | 6.6x#8 | 1360.4x#5 | -58.4%#5 | 1.2%#3 | -33908.5%#5 | -178.5%#9 | — | — | — | — |
| CING | $74M#8 | — | 3.1x#7 | — | — | -35.6%#8 | — | -95.7%#6 | — | — | — | — |
| SKYE | $73M#9 | — | — | — | — | -110.5%#11 | — | — | — | — | — | — |
| PMVP | $72M#10 | — | 1.0x#4 | — | — | -32.0%#7 | — | -108.7%#7 | — | — | — | — |
| PLRX | $69M#11 | — | 0.5x#1 | — | — | -29.0%#6 | — | 101.6%#1 | — | — | — | — |
| TENX | $69M#12 | — | 0.6x#2 | — | — | -198.9%#12 | — | -46.3%#3 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议